Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.73 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.50 |
| ▸ | TUBB | P07437 | 1/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.50 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8727409 | 0.84 | SMPD3 (1.00) | SMPD3MAP3K11KDM4EALDH1A1NISCH | |
| SCHEMBL770667 | 0.81 | SMPD3 (0.66) | SMPD3MAP3K11KDM4EALDH1A1GAA | |
| SCHEMBL8687763 | 0.79 | SMPD3 (0.51) | SMPD3MAP3K11BRD4KDM4EALDH1A1 | |
| SCHEMBL8687770 | 0.79 | SMPD3 (0.51) | SMPD3MAP3K11BRD4KDM4EALDH1A1 | |
| SCHEMBL6630552 | 0.78 | SMPD3 (0.62) | SMPD3BRD4KDM4EALDH1A1CCNB2 | |
| SCHEMBL12714764 | 0.77 | SMPD3 (0.60) | SMPD3MAP3K11KDM4EALDH1A1TDP1 | |
| SCHEMBL5803059 | 0.77 | SMPD3 (0.69) | SMPD3MAP3K11KDM4EALDH1A1GAA | |
| SCHEMBL8687338 | 0.76 | SMPD3 (0.48) | SMPD3MAP3K11BRD4KDM4EALDH1A1 | |
| SCHEMBL8687346 | 0.76 | SMPD3 (0.48) | SMPD3MAP3K11BRD4KDM4E | |
| SCHEMBL28494454 | 0.76 | NISCH (0.62) | SMPD3BRD4KDM4EALDH1A1NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-110404062-A | Immunomodulator and application thereof | UNIV QUEENSLAND | 2019-11-05 | — | — | CN | disclosed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10022356-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-07-17 | — | — | US | disclosed |
| CN-105753787-B | Tumor-targeting drug Combretastatin A4 derivatives | 南京圣和药业股份有限公司 | 2018-05-15 | — | — | CN | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-01-21 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| CN-102190625-B | Stilbene tumor targeted medicine Combretastatin A4 analogs | NANJING SANHOME PHARMACEUTICAL CO LTD | 2013-08-28 | — | — | CN | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-4956470-A | BACTERICIDES, FUNGICIDES, ANTHELMINTICS, ANTIPROTOZOA AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1990-09-11 | — | — | US | disclosed |
| US-4814332-A | PARASITICIDES | HOFFMAN-LA ROCHE INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0253084-A2 | 1,3-Disubstituted imidazolium salts | F. HOFFMANN-LA ROCHE AG (CH) | 1988-01-20 | — | — | EP | disclosed |
| CN-87103528-A | 1, the 3-3-disubstituted imidazolium salts | — | 1987-12-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | BRAF, NRAS, RAF1 | SMPD3 2105/4885MAP3K11 42/4885BRD4 420/4885 |
| US-10022356-B2 | Compounds for treatment of cancer | BRAF, NRAS, RAF1 | SMPD3 2105/4885MAP3K11 42/4885BRD4 420/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | SMPD3 221/4885MAP3K11 776/4885BRD4 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.